INDIANAPOLIS, Nov. 15, 2010 /PRNewswire-FirstCall/ — Eli Lilly
and Company (NYSE:
LLY) today announced that the trial on the validity of the
compound patent for Alimta® (pemetrexed for injection) before
the U.S. District Court for the District of Delaware ended this
afternoon with a ruling from the court that judgment would be
entered in Lilly’s favor, thereby upholding the patent’s validity.
The decision came in the case of Eli Lilly and Company et al v.
Teva Parenteral Medicines Inc., et al. The patent provides
protection for Alimta until July of 2016.
“We are pleased that the District Court has now confirmed the
validity of Alimta’s compound patent,” said Robert A. Armitage,
senior vice president and general counsel for Lilly. “We continue
to emphasize that protection of intellectual property rights is
extremely important to the biopharmaceutical industry and the
patients we serve. These rights provide assurances of market
exclusivity that help support the development of the next
generation of innovative medicines to treat unmet medical
needs.”
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of pharmaceutical products by applying the latest
research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered
in Indianapolis, Ind., Lilly provides answers – through
medicines and information – for some of the world’s most
urgent medical needs. Additional information about Lilly is
available at www.lilly.com. C-LLY
This release contains forward-looking statements regarding the
U.S. Alimta patent litigation. These statements are based on
management’s current expectations but actual results may differ
materially. There can be no assurance that the company will
prevail in any appeal. Also, the comp
‘/>”/>
SOURCE